Introduction
Allogeneic hematopoietic progenitor cell transplantation is now an established treatment for many hematological malignancies, bone marrow failure syndromes and metabolic diseases. 1 Its development from experimental novelty in the 1950s and 1960s to first-line therapy today is owing to many factors, including: the establishment of experienced transplant centers, advances in supportive care, antimicrobial therapy and transfusion technology, and the formation of unrelated adult donor registries and cord blood banks now able to offer over 20 million donors and cord blood units worldwide to those without a HLA-identical sibling donor. 2 Along with increasing use of haplo-identical donors, 3 this expansion of available donor options means that, in the developed world at least, very few patients in need of a transplant should go without.
Despite this progress, transplant failure remains a devastating complication, whether through graft rejection or failure of the graft-vs-malignancy effect, leading to disease relapse. 4 Outcomes in these circumstances can be very poor, with dire prospects of long-term survival in both groups. 5 Primary graft failure has a particularly dismal oneyear survival (11% in one study). 6 In these groups of patients, a second allograft is a reasonable option for clinicians hoping to rescue hematopoietic function or reestablish disease control. [7] [8] [9] [10] [11] [12] [13] [14] [15] The number of second or subsequent allogeneic transplants performed varies by country: data published by the British Society for Bone Marrow Transplantation show 'non-1st' allografts to account for 7% of all transplant activity in the UK and Northern
Ireland in 2010. 16 Anthony Nolan has consistently found the rate of second hematopoietic progenitor cell donations requested from its unrelated adult donors to be between 4% and 7% each year (internal audit).
A few studies have addressed second allografts from the perspective of the donor.
Early reports focused on transplant yields and donor hematological indices. A small study of 16 donors by Stroncek in 1991 showed a significant difference in red cell transfusion requirements and a slight reduction in hemoglobin levels between first and second-time bone marrow (BM) donors. 17 In 1997 Stroncek published again on second time donors, this time focusing on 19 volunteer peripheral blood stem cell (PBSC) donors. 18 Harvest yields were found to be equivalent between first and second donations, and routine blood counts were also unchanged. No difference in adverse reactions was reported between first and second donations, but numbers were, of course, too low to ascertain anything other than a very large difference.
Anderlini et al (1997) published similar findings on harvest yields and adverse events in a study of 13 PBSC donors, concluding that second PBSC collections were 'feasible, similarly tolerated and (able to) provide comparable apheresis yields'. The study protocol was reviewed by the Institutional Review Board at Anthony
Nolan, who deemed that ethical approval was not necessary.
Statistics
Univariate analyses of donor and patient factors influencing subsequent HPC donation requests were performed using a chi-squared test for binomial variables and logistic regression for multinomial categorical variables (e.g. disease).
Multivariate analysis was performed using binary logistic regression. A timedependent cumulative hazard plot for subsequent HPC donation request was modeled using the Kaplan-Meier method, and Cox regression analysis was performed to compare the hazard of subsequent donation requests between PBSC and BM as route of initial donation. Rates of serious adverse events between first time and subsequent HPC donors were compared using a chi-squared test. Harvest yields between first and subsequent donations were compared using a paired t-test. Table 1 summarizes donor and patient characteristics for two groups. The first comprises those donations where only a single donation episode occurred during the study period (n=2373). The second group includes those donations where a further donation was subsequently requested for the same recipient (n=111).
Results

Donor and patient characteristics
For the single donation-only group, the median patient age was 46 years (range 0-74), and 15% were pediatric. Acute leukemia accounted for almost half (47.6%) of transplant indications; non-malignant indications accounted for 9.5%. 22.6% of donations were by BM harvest. The median donor age was 35 years, and the majority of donors were male (76.8%) and CMV negative (67.7%), reflecting donor selection practice. Slightly higher numbers of donations were given in the latter half of the study period than the former, reflecting an increase in usage of unrelated donors in general.
Subsequent donation requests
The median time to subsequent donation request for the same recipient was 179 days (range 21 to 4016 days, interquartile range 306) from the day of first transplant.
73% of requests were made within one year of the first donation, and 91% within two years. Figure 1 shows a cumulative hazard curve (limited to 1000 days) with an event defined as the registry receiving a subsequent donation request. The median age of those requiring a subsequent donation was 42 (range 0-68). 87.4% were adults.
Indications for second allogeneic transplant included primary graft failure (11.7%), secondary graft failure (53.2%), disease relapse (30.6%) and other (1.8%). This latter group included two cases of secondary acute myeloid leukaemia and one case of refractory BK virus and CMV infection on a background of mixed donor chimerism.
In 3 cases (2.7%), the indication for second allograft could not be established.
The main disease categories in the patient group requiring a subsequent donation included acute myeloid leukemia (32.4%, n=36), acute lymphoblastic leukemia (11.7%, n=13), myelodysplasia (11.7%, n=13), non-Hodgkin lymphoma (10.8%, n=12), aplastic anemia (9%, n=10) and chronic myeloid leukemia (6.3%, n=7).
83.8% of recipients were transplanted for a malignant condition.
Of those recipients of a second donation 44.2% received BM for their first allograft, but only 12.8% received BM for their second. 10.5% received BM on both occasions, 33.7% received BM for the initial allograft and PBSC for the subsequent, 2.3%
received PBSC for the initial allograft and BM for the subsequent, and 53.5%
received PBSC for both allografts.
Donor and patient characteristics associated with subsequent donation requests
A summary of the univariate analysis of donor and patient characteristics associated with subsequent donation requests is shown in table 1. There was no statistically significant effect of year of initial donation, patient age (either </>46 or pediatric/adult), patient gender, donor age, donor gender, donor CMV status or HLA match. However, the route of donation had a significant effect: those being called for second donation were more likely to have donated bone marrow for their first donation (OR=2.14, p=<0.001). In addition, those donating to patients with nonmalignant conditions (OR=2.03, P=0.007), and in particular aplastic anemia (OR=2.23, p=0.032) had a significantly higher likelihood of having a request for a second donation.
Multivariate analysis
Only route of donation and patient disease were considered on multivariate analysis, as the other variables examined did not have a statistically significant effect or trend with subsequent donation requests. Because of this heterogeneity of disease groups in the study cohort, and the relatively small numbers in individual disease groups, patient disease divided into malignant and non-malignant was used in the multivariate analysis.
On multivariate analysis, donation of BM was again found to be a significant influence (OR=2.00, p=0.001), but the effect of non-malignant disease retained only a statistical trend (OR=1.62, p=0.08).
BM vs PBSC
In order to further explore the association of graft choice at initial donation with a subsequent donation request, baseline characteristics were compared ( In view of the preference for bone marrow for both pediatric malignant and nonmalignant indications, the analysis was repeated for adult malignancies alone ( figure   3 ). Again, overall, those donating bone marrow at initial donation were more likely to 
Comparison of harvest yields between donations
Harvest yields were only compared for those donors undergoing PBSC on both occasions. The main reason for excluding bone marrow donors from this analysis was due to the small number of donors donating bone marrow on both occasions (n=11). In addition, there was variation in the units of harvest yield between donations: for some bone marrow collections, the units of yield used was total nucleated cells (TNC), but for other collections CD34 count was used.
50 donors donated PBSC on both occasions, of which data on harvest yields were available for 46 (38 male, 8 female). All donors received at least 4 days of granulocyte colony stimulating factor (G-CSF) at a dose of 10µg/kg once daily.
Those requiring a second day of collection received a fifth dose following the first collection. 
Discussion
This study presents an in-depth review of subsequent HPC donations in a large cohort of unrelated donors. We have found that donors who donate BM appear to have greater odds of being requested to make a subsequent donation, when compared to those who donate PBSC. Although there was also a trend toward increased subsequent donation requests in non-malignant conditions, this effect of BM as graft choice persists even when pediatric and non-malignant cases are excluded from analysis. This effect appears to be predominantly attributable to graft failure, which has a well-documented association with BM as a graft source. 28 There has been much recent discussion within the transplant community of preferences regarding route of donation, whether BM or PBSC. Traditionally, BM has been preferred for pediatric patients, 29 as well as those with non-malignant conditions where a graft-vs-disease effect is neither required nor desirable. 30 By contrast, PBSC is the preferred product in many adult malignancies. 15, 31 The majority of studies supporting such practices are based on retrospective analyses of registry data, many of which are now outdated. Randomized prospective data were relatively lacking until the recent publication of the results of a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) study, which compared PBSC to BM as HPC source for transplantation in patients with acute leukemia, myelodysplasia, chronic myeloid or myelomonocytic leukemia, or myelofibrosis. Importantly, no difference in overall survival was found between the two groups. However, as a route of donation, BM was associated with more death from graft failure compared to PBSC, but less death from acute or chronic graft vs. host disease. 28 The authors concluded that specific patient characteristics might influence the choice of stem-cell source. Of note, they suggested that BM might be the HPC source of choice for patients who have had previous immunosuppressive chemotherapy (and are thus at lower risk of graft failure). As a result, it is possible that the use of BM may increase again, reversing the trend of the last few years.
For a transplant physician selecting a donor, the prime concern is the prognosis of their patient. It falls, then, to harvest centers and unrelated donor registries to consider the welfare of unrelated donors when making the final decision on harvest route. A number of donor factors must be taken into consideration, not least the health of the donor, including the presence of pre-existing medical conditions that may preclude a particular route of donation. Of the serious adverse events that we encountered, one (pancreatic cancer several years post-donation) is very unlikely to be related to donation. Two others (severe, but asymptomatic, thrombocytopenia and the requirement for a central line under general anesthetic) although definitely related to the donation, did not result in harm to the donor. Excluding these three events from the analysis renders the difference between adverse events non-significant. Furthermore, our study was underpowered to detect a meaningful difference in adverse events between first and second donations: such a study urgently needs to be repeated in a far larger cohort of donors. There are a few other limitations in interpreting these results: data for the whole cohort on disease status at transplant, disease phenotype and conditioning intensity were unavailable, as was data on ABO blood group matching. Our study would, by design, include only those who were deemed healthy enough to merit a subsequent donation request, and thus it is possible that selection bias may confound these results. However, it is difficult to see how this might differ depending on whether the recipient received BM or PBSC. One further limitation is that there is likely to be a cohort of subsequent donations missed by the study, namely from non-UK transplant centers requesting a non-Anthony Nolan donor for the subsequent donation, when the first donation was provided by Anthony Nolan.
Whilst we would not currently suggest that donor registries and harvest centers advise against bone marrow as a route of donation, our findings have implications when counseling and consenting donors. Being requested for a second donation is considered an undesirable event in itself, carrying the additive risk of donationrelated adverse events as well as inconvenience to the donor, who may need to give up time from work or family for donation.
This study also contributes to an interesting ethical dilemma: how should physicians and donor registries balance the respective risks to the patient and their unrelated donor? When does the potential increased benefit to a patient from a particular route of donation outweigh the chance of a higher risk of serious adverse reactions in the donor, including long-term disability, as well as the higher chance of being requested for a second donation suggested by our study? And by telling donors that a particular route of donation may be more beneficial for the patient, are we placing them under undue emotional duress to select a particular route of harvest that may be of greater detriment to their health?
These are difficult questions to answer, and further evidence and debate is required before a consensus opinion is achieved internationally. In the meantime, it is important for donor registries and harvest physicians to be as open as possible with donors about the existing evidence for both routes of donation, and allow donors to make an informed decision without undue emotional bias.
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Tables
The study protocol was reviewed by the Institutional Review Board at Anthony
Statistics
Donor variables that had more than two categories (degree of HLA match, and age) were summarized to dichotomous categorical variables in a fashion that reflects standard transplant practice. 26, 27 These were: donor age ≤30
and >30 and HLA match 0 or ≥1 mismatches. Patient age was similarly categorized using the median (46) as a cut-off, i.e. ≤46 and >46, and an analysis of pediatric (<18 years old) vs adult was also performed.
Univariate analyses of donor and patient factors influencing subsequent HPC donation requests were performed using a chi-squared test for binomial variables and logistic regression for multinomial categorical variables (e.g. disease). Multivariate analysis was performed using binary logistic regression.
Only those variables with at least a statistical trend towards association with subsequent donation request (p≤0.1) were entered into the multivariate analysis. Associations between variables that potentially predicted subsequent donation requests were examined to look for collinearity. A timedependent cumulative hazard plot for subsequent HPC donation request was modeled using the Kaplan-Meier method, and Cox regression analysis was performed to compare the hazard of subsequent donation requests between PBSC and BM as route of initial donation. This latter analysis controlled for the potentially confounding effect of a change in graft selection practice (from BM to PBSC) over the study period. Rates of serious adverse events between first time and subsequent HPC donors were compared using a chi-squared test. Harvest yields between first and subsequent donations were compared using a paired t-test.
All statistical analyses were performed using PASW statistics v.18.0.
